Publication | Closed Access

Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial

Percutaneous Coronary InterventionThrombosisOpen-label TrialCardiovascular DiseaseSecondary PreventionPharmacologyClinical TrialsCardiovascular PharmacologyPharmacotherapyPlatelet AntagonistMedicineAnticoagulantAtherosclerosisCoronary Artery DiseaseAcute Myocardial Infarction